1. Home
  2. ASTL vs ALLO Comparison

ASTL vs ALLO Comparison

Compare ASTL & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Algoma Steel Group Inc.

ASTL

Algoma Steel Group Inc.

HOLD

Current Price

$4.71

Market Cap

474.3M

Sector

Industrials

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.26

Market Cap

539.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASTL
ALLO
Founded
1902
2017
Country
Canada
United States
Employees
2818
N/A
Industry
Steel/Iron Ore
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
474.3M
539.4M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
ASTL
ALLO
Price
$4.71
$2.26
Analyst Decision
Strong Buy
Analyst Count
0
15
Target Price
N/A
$8.35
AVG Volume (30 Days)
918.1K
14.8M
Earning Date
05-07-2026
05-12-2026
Dividend Yield
1.11%
N/A
EPS Growth
N/A
34.09
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$23.04
$142,416.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.02
$0.86
52 Week High
$7.25
$4.46

Technical Indicators

Market Signals
Indicator
ASTL
ALLO
Relative Strength Index (RSI) 56.01 45.85
Support Level $4.29 $1.92
Resistance Level $4.73 $2.71
Average True Range (ATR) 0.23 0.35
MACD -0.02 -0.04
Stochastic Oscillator 45.00 15.71

Price Performance

Historical Comparison
ASTL
ALLO

About ASTL Algoma Steel Group Inc.

Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from United States. The company generates the majority of its revenue from the sale of Steel sheets and strips.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: